BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

NCT02052219 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy

Interventions

DRUG: Blisibimod
DRUG: Placebo

Sponsor

Anthera Pharmaceuticals